<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293771</url>
  </required_header>
  <id_info>
    <org_study_id>1708018495</org_study_id>
    <nct_id>NCT03293771</nct_id>
  </id_info>
  <brief_title>Transgender Post-reassignment Urogynecologic Measures and Perceptions</brief_title>
  <official_title>Assessment of Postoperative Urologic and Pelvic Floor Complaints in Male-to-female Transgender Patients: a Mixed Methods Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this mixed methods study for transgender women after gender confirmation
      surgery is to characterize and subsequently create a validated screening questionnaire for
      postoperative urologic and pelvic floor symptoms. For individuals who seek gender-confirming
      treatment, about 13% undergo genital surgery for cosmetic purposes with or without
      gonadectomy, and this number is increasing. Patient satisfaction following surgery is high,
      particularly regarding sexual and cosmetic outcomes; however, unexpected negative functional
      outcomes such as bowel and bladder dysfunction and pelvic organ prolapse impact overall
      patient satisfaction. The available information suggests that 16-33% of patients experience
      incontinence postoperatively, with stress predominance, 32-47% experience abnormal voiding,
      and 24-66% experience overactive bladder symptoms. Outside of the typically assessed voiding
      symptoms, unique complaints of MTF postoperative patients include obstructive voiding
      symptoms due to urethral stenosis, persistent perimeatal erectile tissue, prostatic
      hypertrophy, and irritation from neovaginal tissue. Additionally, may of these patients
      develop symptomatic neovaginal prolapse, requiring re-suspension. We suggest that further
      clarification regarding MTF postoperative urologic and pelvic floor complaints can be
      achieved via a mixed methods approach. By using focus group interviews to create specific
      evaluative questions for this unique population, we can then prospectively assess patients
      undergoing surgery via a national multicenter sampling strategy. The goal of the study is to
      better understand the unique symptoms these women experience and create a validated, reliable
      screening questionnaire to monitor patients after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Weeks</target_duration>
  <primary_outcome>
    <measure>Stage 1: Focus groups</measure>
    <time_frame>3 months</time_frame>
    <description>Characterization of genital, urologic, bowel, and sexual symptoms following male-to-female gender confirmation surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Questionnaire testing</measure>
    <time_frame>12 months</time_frame>
    <description>Validity and reliability testing of new questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of symptoms</measure>
    <time_frame>15 months</time_frame>
    <description>Frequency and severity of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between surgical technique and symptoms</measure>
    <time_frame>15 months</time_frame>
    <description>Relationship between surgical technique and symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of hormonal therapy usage and symptoms</measure>
    <time_frame>15 months</time_frame>
    <description>Effect of hormonal therapy usage and symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time since surgery and development of symptoms</measure>
    <time_frame>15 months</time_frame>
    <description>Length of time since surgery and development of symptoms</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gender Identity Disorder of Adult</condition>
  <condition>Voiding Disorders</condition>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Stage 1 Focus Groups</arm_group_label>
    <description>The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Questionnaire Groups</arm_group_label>
    <description>Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Focus group interviews</intervention_name>
    <description>Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.</description>
    <arm_group_label>Stage 1 Focus Groups</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Questionnaire packet</intervention_name>
    <description>Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.</description>
    <arm_group_label>Stage 2 Questionnaire Groups</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stage 1 (Focus group) participants will be comprised of healthy volunteers from the
        transgender community who have completed male-to-female gender confirmation surgery. They
        will be recruited through local clinics, physician referral, or community support groups.

        Stage 2 (Questionnaire) participants will be recruited through multiple transgender centers
        at time of surgical scheduling or within 4 weeks after male-to-female gender confirmation
        surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 1 -- Male-to-female transgender women who are at least 4 weeks postoperative
             following genital surgery for gender confirmation

          -  Stage 2 -- Male-to-female transgender women who are scheduled to undergo surgery or
             are within 4 weeks postoperative

          -  Both stages -- Minimum age 18 years old

          -  Both stages -- English fluency

          -  Both stages -- Reliable contact information and/or permanent residence

        Exclusion Criteria:

          -  Preexisting pelvic pathology, including abnormal anatomy or baseline voiding
             dysfunction

          -  Urinary or intestinal problems prior to surgery lasting greater than 6 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study participants involve transgender individuals who were born phenotypically male but identify as female.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Huber, MD</last_name>
    <phone>212-746-5352</phone>
    <email>sah2757@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Huber, MD</last_name>
      <phone>212-746-5352</phone>
      <email>sah2757@med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Selvaggi G, Bellringer J. Gender reassignment surgery: an overview. Nat Rev Urol. 2011 May;8(5):274-82. doi: 10.1038/nrurol.2011.46. Epub 2011 Apr 12. Review.</citation>
    <PMID>21487386</PMID>
  </reference>
  <reference>
    <citation>Clements-Nolle K, Marx R, Katz M. Attempted suicide among transgender persons: The influence of gender-based discrimination and victimization. J Homosex. 2006;51(3):53-69.</citation>
    <PMID>17135115</PMID>
  </reference>
  <reference>
    <citation>Kailas M, Lu HMS, Rothman EF, Safer JD. PREVALENCE AND TYPES OF GENDER-AFFIRMING SURGERY AMONG A SAMPLE OF TRANSGENDER ENDOCRINOLOGY PATIENTS PRIOR TO STATE EXPANSION OF INSURANCE COVERAGE. Endocr Pract. 2017 Jul;23(7):780-786. doi: 10.4158/EP161727.OR. Epub 2017 Apr 27.</citation>
    <PMID>28448757</PMID>
  </reference>
  <reference>
    <citation>Revol M, Servant JM, Banzet P. [Surgical treatment of male-to-female transsexuals: a ten-year experience assessment]. Ann Chir Plast Esthet. 2006 Dec;51(6):499-511. Epub 2006 Apr 19. French.</citation>
    <PMID>16626849</PMID>
  </reference>
  <reference>
    <citation>Hess J, Rossi Neto R, Panic L, Rübben H, Senf W. Satisfaction with male-to-female gender reassignment surgery. Dtsch Arztebl Int. 2014 Nov 21;111(47):795-801. doi: 10.3238/arztebl.2014.0795.</citation>
    <PMID>25487762</PMID>
  </reference>
  <reference>
    <citation>Goddard JC, Vickery RM, Qureshi A, Summerton DJ, Khoosal D, Terry TR. Feminizing genitoplasty in adult transsexuals: early and long-term surgical results. BJU Int. 2007 Sep;100(3):607-13.</citation>
    <PMID>17669144</PMID>
  </reference>
  <reference>
    <citation>Buncamper ME, van der Sluis WB, van der Pas RS, Özer M, Smit JM, Witte BI, Bouman MB, Mullender MG. Surgical Outcome after Penile Inversion Vaginoplasty: A Retrospective Study of 475 Transgender Women. Plast Reconstr Surg. 2016 Nov;138(5):999-1007.</citation>
    <PMID>27782992</PMID>
  </reference>
  <reference>
    <citation>Jarolím L, Šedý J, Schmidt M, Naňka O, Foltán R, Kawaciuk I. Gender reassignment surgery in male-to-female transsexualism: A retrospective 3-month follow-up study with anatomical remarks. J Sex Med. 2009 Jun;6(6):1635-1644. doi: 10.1111/j.1743-6109.2009.01245.x. Epub 2009 Mar 30.</citation>
    <PMID>19473463</PMID>
  </reference>
  <reference>
    <citation>Rossi Neto R, Hintz F, Krege S, Rubben H, Vom Dorp F. Gender reassignment surgery--a 13 year review of surgical outcomes. Int Braz J Urol. 2012 Jan-Feb;38(1):97-107.</citation>
    <PMID>22397771</PMID>
  </reference>
  <reference>
    <citation>Hoebeke P, Selvaggi G, Ceulemans P, De Cuypere G, T'Sjoen G, Weyers S, Decaestecker K, Monstrey S. Impact of sex reassignment surgery on lower urinary tract function. Eur Urol. 2005 Mar;47(3):398-402. Epub 2004 Dec 2.</citation>
    <PMID>15716207</PMID>
  </reference>
  <reference>
    <citation>Lawrence AA. Patient-reported complications and functional outcomes of male-to-female sex reassignment surgery. Arch Sex Behav. 2006 Dec;35(6):717-27. Epub 2006 Nov 16.</citation>
    <PMID>17109225</PMID>
  </reference>
  <reference>
    <citation>Horbach SE, Bouman MB, Smit JM, Özer M, Buncamper ME, Mullender MG. Outcome of Vaginoplasty in Male-to-Female Transgenders: A Systematic Review of Surgical Techniques. J Sex Med. 2015 Jun;12(6):1499-512. doi: 10.1111/jsm.12868. Epub 2015 Mar 26. Review.</citation>
    <PMID>25817066</PMID>
  </reference>
  <reference>
    <citation>Kuhn A, Santi A, Birkhäuser M. Vaginal prolapse, pelvic floor function, and related symptoms 16 years after sex reassignment surgery in transsexuals. Fertil Steril. 2011 Jun;95(7):2379-82. doi: 10.1016/j.fertnstert.2011.03.029. Epub 2011 Apr 2.</citation>
    <PMID>21458798</PMID>
  </reference>
  <reference>
    <citation>Kuhn A, Hiltebrand R, Birkhäuser M. Do transsexuals have micturition disorders? Eur J Obstet Gynecol Reprod Biol. 2007 Apr;131(2):226-30. Epub 2006 May 5.</citation>
    <PMID>16678333</PMID>
  </reference>
  <reference>
    <citation>Dietrich W, Haitel A, Huber JC, Reiter WJ. Expression of estrogen receptors in human corpus cavernosum and male urethra. J Histochem Cytochem. 2004 Mar;52(3):355-60.</citation>
    <PMID>14966202</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Sarah A. Huber</investigator_full_name>
    <investigator_title>Fellow - Female Pelvic Medicine and Reconstructive Surgery</investigator_title>
  </responsible_party>
  <keyword>Transgender women</keyword>
  <keyword>Male-to-female</keyword>
  <keyword>Gender confirmation surgery</keyword>
  <keyword>Voiding disorder</keyword>
  <keyword>Vaginal dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

